Devyser Diagnostics Q4: A robust quarter for the overlooked high-performer

Research Update

2023-02-22

15:07

Redeye is positive to Devyser’s Q4 report as the company continues to deliver well on its key metrics and demonstrates a progress in line with its financial targets. Sales came in line, and OPEX was overall in check compared to our estimates. We lower our WACC based on a review of Redeye Quality Rating and update our fair value range accordingly.

OB

Oscar Bergman

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.